---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-270798"
form_type: "8-K"
ticker: "SNSE"
cik: "0001829802"
company_name: "Sensei Biotherapeutics, Inc."
filed_at: "2023-11-06T23:59:59+00:00"
generated_at: "2026-06-08T21:26:23.049015+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Sensei Biotherapeutics board unanimously rejects Newtyn's $1.00/share takeover bid

## Summary
- Received unsolicited proposal from Newtyn Management to acquire all shares at $1.00/share in cash.
- Board unanimously determined proposal substantially undervalues the company and its future prospects.
- Company believes it is well-positioned to execute strategy and create long-term value for stockholders.
- Rejection formalized on November 6, 2023; no further terms disclosed.

## SEC filing metadata
- accession: 0001193125-23-270798
- form_type: 8-K
- ticker: SNSE
- cik: 0001829802
- company_name: Sensei Biotherapeutics, Inc.
- filed_at: 2023-11-06T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1829802/000119312523270798/0001193125-23-270798-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1829802/000119312523270798/d471756d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-270798
- JSON: https://secwatch.observer/filing/0001193125-23-270798.json
- Plain text: https://secwatch.observer/filing/0001193125-23-270798.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.